- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
TNF Inhibitor linked to Remission in Early axSpA regardless of Gut Inflammation: Study

A new study published in the journal of Arthritis & Rheumatology showed that early treatment with a TNF inhibitor led to remission in most patients with active axial spondyloarthritis (axSpA), regardless of baseline gut inflammation. Intestinal inflammation did not impact sustained remission rates, and about 75% of patients relapsed after stopping treatment.
The patients with spondyloarthritis experience pauci-articular peripheral arthritis or enthesitis, as well as inflammatory back discomfort. Long-term osteoproliferation and ankylosis of the spine and sacroiliac joint can result from persistent inflammation of the axial skeleton. Remarkably, those with persistent intestinal inflammation were more likely to begin anti-TNFα treatment and had a greater chance of developing ankylosing spondylitis (AS). Thus, to assess the effectiveness of tight-control, quick escalation to TNF suppression in early axial spondyloarthritis in connection to gut inflammation, this study was carried out.
The GO-GUT trial was conducted in treatment-naïve axSpA patients with high disease activity and symptom duration of less than a year. The patients had ileocolonoscopies at baseline, and the gut mucosa was examined histopathologically. After that, each patient got two separate NSAIDs at the recommended dosage for four weeks. Monotherapy with 50 mg golimumab every 4 weeks was started if inactive disease (defined as Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP <1.3) or clinically significant improvement (ΔASDAS-CRP score > 1.1 resulting in low disease activity (ASDAS-CRP <2.1)) could not be obtained.
The patients were monitored until the completion of the experiment or maintained clinical remission (ASDAS-CRP <1.3 at two consecutive visits spaced 12 weeks apart). All medication was stopped after a prolonged clinical remission was achieved, and the prospect of a drug-free remission was assessed.
The trial involved a total of 58 patients. In 28.6% of patients, there was microscopic intestinal inflammation, primarily acute inflammation. It was necessary to escalate treatment to golimumab for 72.7% of patients. Regardless of gut inflammation, 61.8% of patients achieved the primary trial objective of prolonged clinical remission. 78.1% of patients experienced a disease recurrence within a year after stopping treatment.
Overall, regardless of whether microscopic gut inflammation is present or not, a treat-to-target strategy can elicit high percentages of durable clinical remission in treatment-naïve early axSpA.
Reference:
Łukasik, Z., De Craemer, A.-S., Renson, T., Deroo, L., Varkas, G., de Hooge, M., Lenaerts, J., Hoorens, A., Cuvelier, C., Ortega, T. L., Carron, P., Van den Bosch, F., & Elewaut, D. (2025). Efficacy of golimumab in early axial spondyloarthritis in relation to gut inflammation (GO-GUT), an early remission induction study. Arthritis & Rheumatology. https://doi.org/10.1002/art.43283
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751